Biogen Reports Top-Line Results from Phase 2 Study of Gosuranemab in Progressive Supranuclear Palsy

CAMBRIDGE, Mass., Dec. 13, 2019 (GLOBE NEWSWIRE) -- Today, Biogen Inc. (Nasdaq: BIIB) announced topline results from the Phase 2 PASSPORT study of gosuranemab (BIIB092) for progressive supranuclear palsy (PSP). The primary endpoint, as...
Source: Drugs.com - Clinical Trials - Category: Pharmaceuticals Source Type: clinical trials